Apellis Pharmaceuticals Inc (APLS) Stake Boosted by Geode Capital Management LLC

Geode Capital Management LLC grew its position in shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 13.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 421,849 shares of the company’s stock after acquiring an additional 48,603 shares during the period. Geode Capital Management LLC owned about 0.75% of Apellis Pharmaceuticals worth $5,564,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. State Board of Administration of Florida Retirement System raised its stake in shares of Apellis Pharmaceuticals by 15.3% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,467 shares of the company’s stock valued at $164,000 after acquiring an additional 1,659 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Apellis Pharmaceuticals by 159.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,903 shares of the company’s stock valued at $38,000 after acquiring an additional 1,785 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Apellis Pharmaceuticals by 35.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,380 shares of the company’s stock valued at $124,000 after acquiring an additional 2,440 shares during the last quarter. Flinton Capital Management LLC bought a new position in shares of Apellis Pharmaceuticals during the fourth quarter valued at about $36,000. Finally, Citigroup Inc. raised its stake in shares of Apellis Pharmaceuticals by 7.1% during the fourth quarter. Citigroup Inc. now owns 50,913 shares of the company’s stock valued at $672,000 after acquiring an additional 3,386 shares during the last quarter. 50.81% of the stock is owned by hedge funds and other institutional investors.

In related news, major shareholder Morningside Venture Investment purchased 441,176 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, March 11th. The shares were bought at an average price of $17.00 per share, for a total transaction of $7,499,992.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.30% of the stock is owned by insiders.

Shares of NASDAQ APLS opened at $18.88 on Friday. Apellis Pharmaceuticals Inc has a 1 year low of $11.45 and a 1 year high of $26.66. The company has a debt-to-equity ratio of 0.16, a quick ratio of 11.89 and a current ratio of 11.89.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, February 26th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65). On average, research analysts forecast that Apellis Pharmaceuticals Inc will post -2.85 earnings per share for the current year.

APLS has been the subject of several recent analyst reports. B. Riley initiated coverage on shares of Apellis Pharmaceuticals in a research note on Tuesday, January 8th. They set a “buy” rating and a $40.00 price objective for the company. Cantor Fitzgerald set a $57.00 price objective on shares of Apellis Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, February 28th. Zacks Investment Research raised shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. JPMorgan Chase & Co. downgraded shares of Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $34.00 price objective for the company. in a research note on Wednesday, January 23rd. Finally, Robert W. Baird initiated coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, March 28th. They set an “outperform” rating and a $45.00 price objective for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Apellis Pharmaceuticals has an average rating of “Buy” and a consensus target price of $42.67.

TRADEMARK VIOLATION NOTICE: This report was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/21/apellis-pharmaceuticals-inc-apls-stake-boosted-by-geode-capital-management-llc.html.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

Further Reading: Systematic Risk and Investors

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.